EPISODE · Apr 30, 2026 · 1 MIN
Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
from TheBrief.Health · host TheBrief.Health
At AAN Annual Meeting 2026, efgartigimod alfa showed durable adolescent gMG responses, with 80% achieving minimal symptom expression by cycle two and consistent improvements across treatment cycles.
What this episode covers
At AAN Annual Meeting 2026, efgartigimod alfa showed durable adolescent gMG responses, with 80% achieving minimal symptom expression by cycle two and consistent improvements across treatment cycles.
NOW PLAYING
Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m